Cargando…

SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER

BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and highly aggressive tumor that occurs most commonly in infants and young children. The prognosis for patients with AT/RT is generally poor, with a five-year survival rate of less than 30%. METHODS: We retrospectively analyzed the clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Juan, Ai, Ruyu, Lai, Mingyao, Hu, Qingjun, Cai, Linbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402340/
http://dx.doi.org/10.1093/noajnl/vdad070.078
_version_ 1785084853778120704
author Li, Juan
Ai, Ruyu
Lai, Mingyao
Hu, Qingjun
Cai, Linbo
author_facet Li, Juan
Ai, Ruyu
Lai, Mingyao
Hu, Qingjun
Cai, Linbo
author_sort Li, Juan
collection PubMed
description BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and highly aggressive tumor that occurs most commonly in infants and young children. The prognosis for patients with AT/RT is generally poor, with a five-year survival rate of less than 30%. METHODS: We retrospectively analyzed the clinical data of patients with AT/RT in the past 10 years at the Guangdong Sanjiu Brain Hospital RESULTS: A total of 18 cases (male/female = 9:9; median age at diagnosis, 3.5 years (range 1-58 years old)) were diagnosed with AT/RT between 2017 and 2023. AT/RT had higher prevalence in children < 36 months (55.6%), and at infratentorial (66.7%). The median follow-up time was 15.5 months, with a range of 2-62 months. Survival analyses demonstrated that patients > 3 years of age (n = 9 (50%)) had median survival time 28months and patients ≤ 3 years of age (n = 9 (50%)) had median- survival time 15 months (p =0.034) The average survival time for disseminated tumor was 15 months, and for patients with localizedtumors was 44 months. (P=0.012) CONCLUSION: Older age, localized tumor improves the survival of patients with AT/RT.
format Online
Article
Text
id pubmed-10402340
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104023402023-08-05 SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER Li, Juan Ai, Ruyu Lai, Mingyao Hu, Qingjun Cai, Linbo Neurooncol Adv Final Category: Screening/Diagnostics/Prognostics BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and highly aggressive tumor that occurs most commonly in infants and young children. The prognosis for patients with AT/RT is generally poor, with a five-year survival rate of less than 30%. METHODS: We retrospectively analyzed the clinical data of patients with AT/RT in the past 10 years at the Guangdong Sanjiu Brain Hospital RESULTS: A total of 18 cases (male/female = 9:9; median age at diagnosis, 3.5 years (range 1-58 years old)) were diagnosed with AT/RT between 2017 and 2023. AT/RT had higher prevalence in children < 36 months (55.6%), and at infratentorial (66.7%). The median follow-up time was 15.5 months, with a range of 2-62 months. Survival analyses demonstrated that patients > 3 years of age (n = 9 (50%)) had median survival time 28months and patients ≤ 3 years of age (n = 9 (50%)) had median- survival time 15 months (p =0.034) The average survival time for disseminated tumor was 15 months, and for patients with localizedtumors was 44 months. (P=0.012) CONCLUSION: Older age, localized tumor improves the survival of patients with AT/RT. Oxford University Press 2023-08-04 /pmc/articles/PMC10402340/ http://dx.doi.org/10.1093/noajnl/vdad070.078 Text en © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: Screening/Diagnostics/Prognostics
Li, Juan
Ai, Ruyu
Lai, Mingyao
Hu, Qingjun
Cai, Linbo
SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
title SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
title_full SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
title_fullStr SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
title_full_unstemmed SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
title_short SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
title_sort sdps-22 the clinical outcomes of atypical teratoid/rhabdoid tumor from one single clinical center
topic Final Category: Screening/Diagnostics/Prognostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402340/
http://dx.doi.org/10.1093/noajnl/vdad070.078
work_keys_str_mv AT lijuan sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter
AT airuyu sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter
AT laimingyao sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter
AT huqingjun sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter
AT cailinbo sdps22theclinicaloutcomesofatypicalteratoidrhabdoidtumorfromonesingleclinicalcenter